You have 9 free searches left this month | for more free features.

Brentuximab Vedotin

Showing 1 - 25 of 296

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Mogamulizumab, Brentuximab vedotin)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides
  • (no location specified)
Dec 7, 2022

Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome Trial in United States (brentuximab vedotin)

Recruiting
  • Mycosis Fungoides
  • +2 more
  • brentuximab vedotin
  • Stanford, California
  • +7 more
Nov 3, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Mycosis Fungoides Trial in Houston (Brentuximab vedotin)

Recruiting
  • Mycosis Fungoides
  • Brentuximab vedotin
  • Houston, Texas
    MD Anderson Cancer Center
Oct 14, 2022

Human Immunodeficiency Virus Trial in Chicago (brentuximab vedotin, Placebo, ART)

Recruiting
  • Human Immunodeficiency Virus
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
    University of Illinois at Chicago
Jul 29, 2022

Hodgkin Lymphoma Trial in Cologne (B-CAP, Brentuximab Vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • Cologne, Germany
    1st Dept. of Medicine, Cologne University Hospital
Aug 5, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Brentuximab Vedotin in Pediatric Hodgkin Lymphoma

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • (no location specified)
Jul 28, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

Terminated
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 7, 2022

Hodgkin Lymphoma Trial in New York (Mocetinostat Plus Brentuximab Vedotin)

Completed
  • Hodgkin Lymphoma
  • Mocetinostat Plus Brentuximab Vedotin
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 10, 2022

Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin

Not yet recruiting
  • T-Cell Lymphoma
  • No intervention
  • Bordeaux, France
  • +10 more
May 24, 2023

Diffuse Cutaneous Systemic Sclerosis Trial (Brentuximab vedotin)

Not yet recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • Brentuximab vedotin
  • (no location specified)
Apr 11, 2022

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

Lymphoma Trial in Berne (Brentuximab Vedotin, BeEAM Regimen)

Recruiting
  • Lymphoma
  • Brentuximab Vedotin
  • BeEAM Regimen
  • Berne, Switzerland
    Department for Medical Oncology University Hospital/Inselspital
Feb 4, 2022

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma Trial in Belgium, France (Brentuximab Vedotin -

Completed
  • Refractory Peripheral T-Cell Lymphoma
  • Relapsed Peripheral T-Cell Lymphoma
  • Brentuximab Vedotin - induction
  • +3 more
  • Antwerpen, Belgium
  • +38 more
Jan 9, 2023

Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

Recruiting
  • Relapsed/Refractory Classical Hodgkin Lymphoma
  • Brentuximab vedotin
  • Goyang, Gyeonggi-do, Korea, Republic of
    Hyeon-Seok Eom
Feb 12, 2022

Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases Trial in Hollywood, Boston, Chapel Hill (Brentuximab Vedotin, CHEP)

Active, not recruiting
  • Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • CHEP
  • Hollywood, Florida
  • +3 more
Nov 30, 2022

Brentuximab Vedotin Intravenous Infusion "Untreated

Active, not recruiting
  • Untreated CD30-Positive Hodgkin's Lymphoma
  • Brentuximab vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Mar 24, 2022

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Doxorubicin, Vincristine)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +3 more
  • Valhalla, New York
    New York Medical College
Sep 27, 2022